Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
Clinical trial NCT03504423 · COMPLETED
Trial details
- NCT number
- NCT03504423
- Sponsor
- Cornerstone Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-09
- Primary completion
- 2021-08-16
- Enrollment
- 528
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.